
FDA Accepts Takeda and Protagonist’s NDA for Rusfertide, a First-in-Class Treatment for Polycythemia Vera
Pivotal Study Shows Significant Improvements in Hematocrit Control and Patient Outcomes What does the future hold for patients with polycythemia vera (PV)? Takeda and Protagonist Therapeutics, Inc. have announced a…












